In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
Excerpts from recent editorials in the United States and abroad: ___ Jan. 26 The Washington Post on Trump's “energy emergency” Oil and gas production in the United States is hitting record highs, ...
We present the investment thesis on Perrigo Company plc- a consumer health company which, we believe, is close to an ...
It would also prohibit a PBM from making payments to a pharmacy ... It also authorizes the Health Policy Commission to assess pharmaceutical manufacturing companies and PBMs.
Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?
In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...
I foresee a stalling of manufacturing and an increase in ... companies can claim regarding biologics; delinking of pharmacy benefit manager revenue from drug prices in Medicare, curbing incentives ...
It would also prohibit a PBM from making payments to a pharmacy ... It also authorizes the HPC to assess pharmaceutical manufacturing companies and PBMs. Pharmaceutical manufacturers and PBMs ...
American healthcare and pharma sector. A final factor worth keeping track of is the Corporate Sustainability Reporting Directive.
We recently compiled a list of the 12 Cheapest Stocks with Biggest Upside Potential. In this article, we are going to take a ...
Based on recent policy signals and statements from incoming administration officials, a picture of potential regulatory and policy changes that ...